

DR REDDY'S LABORATORIES (DRREDDY-IN)

Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals

DETAILED STOCK REPORT

Report Date: 2024-May-05

Last Close 6,349.55 (INR)	Avg Daily Vol 397,865	52-Week High 6,505.90	Trailing PE 20.2	Annual Div 40.00	ROE 21.4%	LTG Forecast --	1-Mo Return 3.7%
2024 May 03 NSE Exchange	Market Cap 1.1T	52-Week Low 4,384.05	Forward PE 19.3	Dividend Yield 0.6%	Annual Rev 271.3B	Inst Own 67.0%	3-Mo Return 5.1%

AVERAGE SCORE


AVERAGE SCORE

8

POSITIVE OUTLOOK: DRREDDY's current score of 8 places it among the top quartile of stocks scored.

Score Averages

Pharmaceuticals Group:	4.8	Large Market Cap:	6.8
Pharma. & Medical Research Sector:	4.7	BSE Sensex Index:	8.1



Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
LUPIN	6	9	9	9	9	
MANKIND	8	9	10	10	9	
DRREDDY	9	10	9	9	8	
TORNTPHARM	5	8	7	7	8	
DIVISLAB	3	5	4	3	3	

HIGHLIGHTS

- The score for Dr Reddy's Laboratories has been on a negative trend from 10 to 8 over the past 13 weeks.
- The recent change in the Average Score was primarily due to a decline in the Risk and Price Momentum component scores.

I/B/E/S MEAN

Hold

34 Analysts



Mean recommendation from all analysts covering the company on a standardized 5-point scale.



PRICE AND VOLUME CHARTS

1-Year Return: 28.2%

5-Year Return: 118.4%



BUSINESS SUMMARY


Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

INDICATOR COMPONENTS

AVERAGE
SCORE

8

The **AVERAGE SCORE** combines the quantitative analysis of five widely-used investment decision making tools: Earnings, Fundamental, Relative Valuation, Risk, and Price Momentum. A simple average of the underlying component ratings is normally distributed to rank stocks on a 1-10 scale (10 being awarded to the most favorable). These factors may be evaluated differently using alternative methodologies and the importance of individual factors varies across industries, market capitalization and investment styles. Additional criteria should always be used to evaluate a stock.



PEER ANALYSIS

Currency in INR

Average Score	Ticker	PRICE MOMENTUM				VALUATION			FUNDAMENTAL		ANALYSTS	
		Price (2024-05-03)	1-Mo Return	3-Mo Return	1-Yr Return	Market Cap	Trailing PE	Forward PE	Dividend Yield	Net Margin	LTG Forecast	I/B/E/S Mean
8	DRREDDY	6,349.55	3.7%	5.1%	28.2%	1.1T	20.2	19.3	0.63%	19.2%	-- Hold	34
3	DIVISLAB	3,950.95	7.2%	6.8%	20.9%	1.0T	75.8	56.6	0.76%	18.5%	-- Sell	21
9	MANKIND	2,314.90	-2.1%	13.7%	--	927.3B	53.8	50.6	--	17.4%	-- Buy	12
8	TORNTPHARM	2,734.70	5.6%	8.3%	65.2%	925.5B	62.0	46.8	1.1%	14.4%	-- Buy	26
9	LUPIN	1,654.75	3.1%	10.1%	133.2%	754.2B	42.2	32.0	0.24%	9.2%	-- Hold	31
7	AUROPHARMA	1,151.65	1.2%	8.0%	86.8%	674.8B	24.4	18.7	0.39%	9.9%	-- Buy	23
6	ALKEM	4,904.00	0.19%	-0.28%	39.4%	586.3B	37.3	31.4	0.92%	12.5%	-- Hold	20
7	ABBOTINDIA	26,146.60	-2.1%	-6.8%	15.9%	555.6B	48.5	47.3	0.69%	19.9%	-- Strong Buy	4
5	GLAXO	2,095.35	6.6%	-9.2%	67.9%	355.0B	69.9	52.2	1.5%	16.0%	-- Hold	4
6	IPCALAB	1,337.70	9.3%	20.7%	88.9%	339.4B	60.1	52.4	0.30%	7.9%	-- Hold	14
4	JBCHEPHARM	1,889.90	12.2%	11.9%	80.3%	293.3B	57.9	51.9	0.54%	15.2%	-- Buy	11
6.5	Average	4,957.28	4.1%	6.2%	62.7%	683.4B	50.2	41.7	0.71%	14.5%	-- Hold	18.2

PEER COMPANIES

ABBOTINDIA	Abbott India	IPCALAB	IPCA Laboratories
ALKEM	Alkem Laboratories	JBCHEPHARM	J B Chemicals
AUROPHARMA	Aurobindo Pharma	LUPIN	Lupin
DIVISLAB	Divi's Laboratories	MANKIND	Mankind Pharma
GLAXO	GlaxoSmithKline	TORNTPHARM	Torrent Pharmaceuticals

EARNINGS

EARNINGS

6


Currency in INR

NEUTRAL OUTLOOK: Mixed earnings expectations and performance.

Earnings Score Averages

Pharmaceuticals Group:	5.8	Large Market Cap:	5.8
Pharma. & Medical Research Sector:	5.5	BSE Sensex Index:	6.7

Earnings Score Trend (4-Week Moving Avg)




Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
LUPIN	8	10	10	10	10	
TORNTPHARM	6	6	7	8	9	
MANKIND	4	4	8	8	8	
DRREDDY	7	7	6	6	6	
DIVISLAB	2	2	5	3	3	

EARNINGS INDICATORS

Earnings Surprises (33.3% weight)

Estimate Revisions (33.3% weight)

Recommendation Changes (33.3% weight)



Last 4 Quarters

# Positive Surprises (>2%)	4
# Negative Surprises (<-2%)	0
# In-Line Surprises (within 2%)	0
Avg Surprise	23.4%

Last 4 Weeks

# Up Revisions	0
# Down Revisions	1
Avg Up Revisions	0.00%
Avg Down Revisions	-2.9%

Last 120 Days


# Broker Upgrades	1
# Broker Downgrades	5

HIGHLIGHTS

- Dr Reddy's Laboratories currently has a relatively neutral Earnings Rating of 6. The average Earnings Rating for its Pharmaceuticals industry is 5.8 and the S&P BSE SENSEX index average is 6.7.
- DRREDDY's current quarter consensus estimate has increased over the past 90 days from 68.87 to 73.29, a rise of 6.4%. Consensus estimates for the Pharmaceuticals industry have moved an average 0.0% during the same time period.
- There have been 1 upward and 5 downward broker recommendation changes for Dr Reddy's Laboratories over the past 120 days.

PRICE TARGET

The chart indicates where analysts predict the stock price will be within the next 12 months, as compared to the current price.




12-Month Price Target

Mean (INR)	5,920.00
High	6,790.00
Low	3,920.00
Target vs. Current	-6.8%
# of Analysts	37


EARNINGS PER SHARE

Earnings per share (EPS) is calculated by dividing a company's earnings by the number of shares outstanding. Analysts tend to interpret a pattern of increasing earnings as a sign of strength and flat or falling earnings as a sign of weakness.

The charts provide a comparison between a company's actual and estimated EPS, including the high and low forecasts.



Quarterly	24-03	24-06
Mean	73.290	82.810
High	89.500	82.810
Low	51.800	82.810
# of Analysts	5	1



Annual	2024	2025
Mean	318.6	334.3
High	346.8	376.5
Low	184.5	222.4
# of Analysts	30	30

MEAN ESTIMATE TREND **ANALYST RECOMMENDATIONS**

	Q 24-03	Q 24-06	Y 2024	Y 2025	Price Target
Current	73.290	82.810	318.6	334.3	5,920.00
30 Days Ago	68.870	81.650	316.9	331.9	5,850.00
90 Days Ago	68.870	81.650	317.0	332.5	5,830.00
% Change (90 Days)	6.4%	1.4%	0.50%	0.50%	1.5%

Current Fiscal Year End: 24-03
Next Expected Report Date: 2024-05-07

I/B/E/S Mean: **Hold (34 Analysts)**

Strong Buy	5
Buy	7
Hold	11
Sell	8
Strong Sell	3

EARNINGS SURPRISES

Comparing a company's actual earnings to the mean expectation of analysts results in a difference referred to as a 'positive' or 'negative' surprise. Research has shown that when a company reports a surprise, it is often followed by more of the same surprise type.

Surprise Summary (Last 12 Quarters)


Surprise Type	Amount	Percent
Positive Quarters (> 2%)	8	66.7%
Negative Quarters (< -2%)	4	33.3%
In-Line Quarters (within 2%)	0	--

Surprise Detail (Last 6 Periods)

Surprise Type	Announce Date	Period End Date	Actual EPS	Mean EPS	Surprise (%)
Positive	2024-01-30	2023-12-31	82.810	73.940	12.0%
Positive	2023-10-27	2023-09-30	88.910	72.490	22.7%
Positive	2023-07-26	2023-06-30	84.360	60.750	38.9%
Positive	2023-05-10	2023-03-31	57.680	48.010	20.1%
Positive	2023-01-25	2022-12-31	74.760	64.730	15.5%
Positive	2022-10-28	2022-09-30	66.980	47.190	41.9%

ANNUAL REVENUE

A pattern of increasing sales in conjunction with a rising EPS may influence a buy recommendation, while flat or falling sales and faltering earnings may explain a sell recommendation. A rising EPS with flat or falling sales may result from increased cost efficiency and margins, rather than market expansion. This chart shows the sales forecast trend of all analysts and the highest and lowest projections for the current and next fiscal year.



	2024	2025
Mean	276.4B	295.5B
High	287.8B	310.5B
Low	240.3B	254.7B
Forecasted Growth	12.0%	19.8%
# of Analysts	31	30


FUNDAMENTAL

FUND-AMENTAL
10

POSITIVE OUTLOOK: Strong fundamentals such as high profit margins, low debt levels, or growing dividends.


Fundamental Score Averages

Pharmaceuticals Group:	5.1	Large Market Cap:	6.3
Pharma. & Medical Research Sector:	5.1	BSE Sensex Index:	7.1



Peers	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Current	3Y Trend
DRREDDY	8	9	9	NR	10	■■■■■■■■■■
MANKIND	NR	NR	NR	NR	10	■■■■■■■■■■
LUPIN	2	2	3	NR	6	■■■■■■■■■■
DIVISLAB	9	8	7	NR	5	■■■■■■■■■■
TORNTPHARM	3	3	4	NR	4	■■■■■■■■■■

FUNDAMENTAL INDICATORS



Revenue Growth	14.3%	Current Ratio	2.5	Oper. Cash Yield	1.9%	Dividend Growth	33.3%
For year over year ending 2023-12		For interim period ending 2023-12		For latest 12 months ending --		For year over year ending 2023-12	
Gross Margin	55.4%	Debt-to-Capital	0.6%	Accruals	18.1%	Dividend Payout	12.7%
For latest 12 months ending 2023-12		For annual period ending 2023-03		For latest 12 months ending 2023-03		For latest 12 months ending 2023-12	
Return On Equity	21.4%	Interest Funding	1.9%	Days Sales In Inv.	180.9	Dividend Coverage	13.2
For interim period ending 2023-12		For interim period ending 2023-06		For annual period ending 2023-03		For annual period ending 2023-03	
Net Margin	19.2%	Interest Coverage	47.3	Days Sales In Rec.	109.5	Current Div. Yield	0.6%
For latest 12 months ending 2023-12		For interim period ending 2023-12		For annual period ending 2023-03		For latest 12 months ending 2024-05	

HIGHLIGHTS

- Dr Reddy's Laboratories currently has a Fundamental Rating of 10, which is significantly more bullish than the Pharmaceuticals industry group average of 5.1.
- The company's gross margin has been higher than its industry group average for each of the past five years.
- The company's current ratio has been higher than its industry group average for each of the past five years.
- The company's operating cash yield has been higher than its industry group average for each of the past five years.
- Of the 198 firms within the Pharmaceuticals industry group, Dr Reddy's Laboratories is among 80 companies that pay a dividend. The stock's dividend yield is currently 0.63%.



RELATIVE VALUATION


POSITIVE OUTLOOK: Multiples significantly below the market or the stock's historic norms.



Relative Valuation Score Averages

Pharmaceuticals Group:	5.2	Large Market Cap:	4.5
Pharma. & Medical Research Sector:	5.2	BSE Sensex Index:	6.0

Relative Valuation Score Trend (4-Week Moving Avg)




Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
DRREDDY	7	8	8	8	8	
LUPIN	3	4	5	5	5	
TORNTPHARM	3	3	3	3	3	
DIVISLAB	2	2	2	2	2	
MANKIND	2	2	2	2	2	

RELATIVE VALUATION INDICATORS

Price to Sales
(33.3% weight)

Trailing PE
(33.3% weight)

Forward PE
(33.3% weight)



Price to Sales	3.8	Trailing PE	20.2	Forward PE	19.3
5-Yr Average	3.6	5-Yr Average	29.4	5-Yr Average	22.9
Rel. to 5-Yr Avg.	7% Premium	Rel. to 5-Yr Avg.	31% Discount	Rel. to 5-Yr Avg.	16% Discount
BSE Sensex Index	3.5	BSE Sensex Index	24.9	BSE Sensex Index	22.8
Rel. to BSE Sensex	11% Premium	Rel. to BSE Sensex	19% Discount	Rel. to BSE Sensex	15% Discount


HIGHLIGHTS

- Dr Reddy's Laboratories currently has a Relative Valuation Rating of 8 which is significantly above the S&P BSE SENSEX index average rating of 6.0.
- Compared to the Pharmaceuticals industry group, DRREDDY is currently trading at a significant discount based on Price to Sales ratio, Trailing P/E, and Forward P/E.
- DRREDDY's Price to Sales ratio of 3.8 represents a 7% Premium to its 5-year average of 3.6.
- DRREDDY's 20.2 Trailing P/E is currently at the low end of its 5-year range (lowest 16.2 to highest 57.8).
- DRREDDY's Forward P/E of 19.3 represents a 16% Discount to its 5-year average of 22.9.

PRICE TO SALES

The most recent week's close price divided by the revenue per share.


Price to Sales: 3.8
 5-Year Average: 3.6
 BSE Sensex Index Average: 3.5
 Pharmaceuticals Group Average: 5.2



TRAILING PE

The most recent week's close price divided by the sum of the four most recently reported quarterly earnings.


Trailing PE: 20.2
 5-Year Average: 29.4
 BSE Sensex Index Average: 24.9
 Pharmaceuticals Group Average: 41.6



FORWARD PE

The most recent week's close price divided by the sum of the four upcoming quarterly consensus estimates.


Forward PE: 19.3
 5-Year Average: 22.9
 BSE Sensex Index Average: 22.8
 Pharmaceuticals Group Average: 36.9



FORWARD PEG

The Forward P/E divided by the five-year forecasted growth rate.

Forward PEG: --
 5-Year Average: 1.1
 BSE Sensex Index Average: 1.5
 Pharmaceuticals Group Average: 1.7



DR REDDY'S LABORATORIES (DRREDDY-IN)

Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals

DETAILED STOCK REPORT

Report Date: 2024-May-05


RISK

POSITIVE OUTLOOK: Consistent return patterns (low volatility).

RISK
8


Risk Score Averages

Pharmaceuticals Group:	6.3	Large Market Cap:	8.4
Pharma. & Medical Research Sector:	6.3	BSE Sensex Index:	9.4



Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
DIVISLAB	10	10	10	10	10	
LUPIN	10	9	10	10	10	
MANKIND	10	10	10	10	10	
TORNTPHARM	10	10	10	10	10	
DRREDDY	9	9	9	9	8	

RISK INDICATORS



Daily Returns (Last 90 Days)		Standard Deviation		Beta vs. BSE Sensex		Correlation vs. BSE Sensex	
Best	4.5%	Last 90 Days	1.30	Positive Days Only	0.24	Last 90 Days	12%
Worst	-3.6%	Last 60 Months	7.79	Negative Days Only	0.30	Last 60 Months	12%
Monthly Returns (Last 60 Months)		Intra-Day Swing (Last 90 Days)		Beta vs. Group		Correlation vs. Group	
Best	26.1%	Average	2.0%	Positive Days Only	0.17	Last 90 Days	15%
Worst	-13.1%	Largest	5.4%	Negative Days Only	-0.11	Last 60 Months	39%

HIGHLIGHTS

- Dr Reddy's Laboratories currently has a Risk Rating of 8 while the S&P BSE SENSEX index has an average rating of 9.4.
- On days when the market is up, DRREDDY shares tend to lag the S&P BSE SENSEX index. However, on days when the market is down, the shares generally decrease less than the index.
- In both short-term and long-term periods, DRREDDY has shown low correlation (≥ -0.1 and $< 0.2\%$) with the S&P BSE SENSEX index. Thus, this stock would provide high levels of diversification to a portfolio similar to the broader market.
- Over the last 90 days, DRREDDY shares have been less volatile than the overall market, as the stock's daily price has fluctuated less than 99% of S&P BSE SENSEX index firms.

RISK ANALYSIS

Peers	Last 90 Days				Last 60 Months		
	Best Daily Return	Worst Daily Return	# Days Up	# Days Down	Largest Intra-Day Swing	Best Monthly Return	Worst Monthly Return
DRREDDY	4.5%	-3.6%	30	30	5.4%	26.1%	-13.1%
DIVISLAB	4.5%	-2.7%	31	29	5.1%	19.4%	-20.3%
LUPIN	4.7%	-2.9%	34	26	7.1%	41.7%	-17.9%
MANKIND	5.7%	-3.9%	34	26	6.9%	25.5%	-3.0%
TORNTPHARM	4.7%	-3.6%	34	26	5.5%	19.0%	-18.5%
BSE Sensex	1.7%	-1.2%	36	23	2.1%	14.4%	-23.1%




PRICE MOMENTUM Currency in INR

NEGATIVE OUTLOOK: Weak recent price performance or entering historically poor seasonal period.

PRICE MOMENTUM
3

Price Momentum Score Averages

Pharmaceuticals Group:	3.4	Large Market Cap:	6.2
Pharma. & Medical Research Sector:	3.3	BSE Sensex Index:	5.5




Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
TORNTPHARM	4	10	7	6	7	
MANKIND	8	10	9	9	6	
LUPIN	5	10	7	7	5	
DRREDDY	4	9	6	4	3	
DIVISLAB	2	5	1	1	1	

PRICE MOMENTUM INDICATORS

Relative Strength
(50% weight)

Seasonality
(50% weight)



Relative Strength Indicator (Scale from 1 to 100)

	DRREDDY	Industry Avg
Last 10 Days	67	54
Last 50 Days	56	53
Last 200 Days	55	53


Average Monthly Return (Last 10 Years)

	May	Jun	Jul
Company Avg	-1.7%	4.3%	0.04%
Industry Avg	-0.63%	3.7%	6.3%
Industry Rank	87 of 99	70 of 98	21 of 99

PRICE PERFORMANCE

Daily close prices are used to calculate the performance of the stock as compared to a relevant index over five time periods.

■ DRREDDY
■ BSE Sensex



	DRREDDY	BSE Sensex
Close Price (2024-05-03)	6,349.55	73,880
52-Week High	6,505.90	75,038
52-Week Low	4,384.05	61,054

- On 2024-05-03, DRREDDY closed at 6,349.55, 2.4% below its 52-week high and 44.8% above its 52-week low.
- DRREDDY shares are currently trading 2.4% above their 50-day moving average of 6,202.79, and 8.8% above their 200-day moving average of 5,837.24.
- The S&P BSE SENSEX index is currently 1.5% below its 52-week high and 21.0% above its 52-week low.

DETAILED STOCK REPORT TIPS

The Stock Report from LSEG is a comprehensive, company-specific analysis that includes a proprietary Stock Rating along with underlying component indicators and supportive data elements. The report is updated daily, although some of the data elements and the ratings are updated weekly.

Average Score

The Stock Reports Plus Average Score combines a quantitative analysis of five widely-used investment decision making tools - Earnings, Fundamental, Relative Valuation, Risk, and Price Momentum. First, a simple average of the five underlying component ratings is calculated. Then, a normal distribution is used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A score of 8 to 10 is considered positive, 4 to 7 is neutral, and 1 to 3 is negative. These five factors may be evaluated differently using alternative methodologies, and the importance of individual factors varies across industry groups, market capitalization and investment styles. Additional criteria should always be used to evaluate a stock.

A company must have sufficient data available for at least three of the five component indicators in order to receive an overall Average Score. Approximately 85% of the stocks within the coverage universe meet the criteria to generate a score.

Indicator Components

The five indicators that comprise the stock rating are displayed. Like the stock rating, the component rating scale is 1 to 10, with 10 being best. A company will receive an 'NR' for No Rating if the required data elements or criteria are not met. A detailed section for each component is included in the report.

Indicator Trends

Within each component section, historical score trends are displayed, typically using a 4-week moving average over a timeframe of the past three years. The dotted orange line indicates the average of the scores over those three years. The most recent occurrences of the best and worst scores are also displayed on the chart in grey boxes to put the current score into historical context.

Next to the trend chart for the company, current score averages are included, along with peer company comparisons of values from 6 months ago, 3 months ago, 1 month ago, the most recent value from 1 week ago, and the current score. The four closest industry peers are presented based on similar market capitalization.

Peer Analysis

- The Refinitiv Business Classification (TRBC) schema is used for industry comparisons. It is designed to track and display the primary business of a corporation by grouping together correlated companies that offer products and services into similar end markets. The system includes 10 Economic Sectors, 28 Business Sectors, 54 Industry Groups, and 136 Industries.
- The Peer Analysis section of the report compares the company to its ten closest peers. The peers are selected from the industry based on similar market capitalization. The peer listing may have fewer than ten companies if there are fewer than ten companies classified within that industry.

Highlights

The automated text-generation system from LSEG creates highlights summarizing the most noteworthy data. The bullets will vary by company and will change from week to week as different criteria are met.

Earnings

The Earnings Rating is based on a combination of three factors: earnings surprises, estimate revisions, and recommendation changes. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have at least two of the three earnings factors in order to receive a score.

- Earnings Surprises - The number of positive and negative surprises within the last 4 periods (quarters or years).
- Estimate Revisions - The number of up and down revisions and the average percentage change of those revisions within a 4 week period.
- Recommendation Changes - The number of broker upgrades and downgrades in the last 120 days.

Price Target

The price target is based on the predictions of analysts covering the stock and shows the high, low and mean price expected within the next 12 months.

Earnings Per Share

The quarterly and annual earnings per share are presented when available, along with the mean, high and low. Quarterly data is displayed for the past 4 quarters (actual) and the next 2 quarters (estimated). Annual data is displayed for the past 2 years (actual) and the next 2 years (estimated).

Mean Estimate Trend

The mean estimates show how the consensus has changed over the past 30 days and 90 days for the upcoming two quarters (when available) and two years. The percentage change is calculated for the company as a means for comparison by measuring the difference between the current consensus estimate and that of 90 days ago.

Analyst Recommendations

The I/B/E/S Mean is the average recommendation of all analysts covering the stock, as provided by I/B/E/S, the Institutional Brokers Estimate System, from LSEG. The recommendations are presented on a five-point standardized scale: strong buy, buy, hold, sell, and strong sell.

Earnings Surprises

- The surprise summary includes the total number of time periods (and percentage) in the last 12 quarters (quarterly) or last 4 years (annual) in which earnings surprises were positive, negative, or in-line. In order to be recognized as a positive or negative surprise, the percent must be greater than 2% above or 2% below the consensus, respectively.
- The surprise detail section includes a listing of the company's quarterly earnings reported for the most recent 6 periods (quarters or years). The consensus analyst estimate is provided to determine if the actual earnings report represented a positive surprise, negative surprise, or in-line result.

Fundamental

The Fundamental Rating is based on a combination of four fundamental component factors: profitability, debt, earnings quality, and dividend. Companies that do not pay a dividend are not penalized. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have at least two of the four fundamental factors present in order to receive a score.

Profitability

- Revenue Growth: $(\text{Net Sales} - \text{Previous Net Sales}) / \text{Previous Net Sales}$
- Gross Margin: $\text{Gross Profit} / \text{Net Sales}$
- Return on Equity: $\text{Net Income} / \text{Total Equity}$
- Net Margin: $\text{Net Profit} / \text{Net Sales}$

Debt

- Current Ratio: $\text{Current Assets} / \text{Current Liabilities}$
- Debt-to-Capital: $\text{Total Debt} / \text{Total Capital}$
- Interest Funding: $(\text{Interest Expense on Debt} + \text{Preferred Cash Dividends}) / \text{Funds from Operations}$
- Interest Coverage: $\text{Earnings before Interest and Taxes} / (\text{Interest Expense on Debt} + \text{Preferred Cash Dividends})$

Earnings Quality

- Operating Cash Yield: $(\text{Operating Cash Flow} - \text{Net Income}) / \text{Net Income}$
- Accruals: $(\text{Net Income} - \text{Operating Cash Flow} - \text{Investing Cash Flow}) / \text{Average Net Operating Assets}$
- Days Sales in Inventory: $365 / (\text{Cost of Goods Sold} / \text{Inventory})$
- Days Sales in Receivables: $365 / (\text{Net Sales} / \text{Receivables})$

Dividend

The company must have a current dividend yield.

- Dividend Growth Rate: $(\text{Dividends per Share} - \text{Previous Dividends per Share}) / \text{Previous Dividends per Share}$
- Dividend Funding: $\text{Dividends} / \text{Operating Cash Flow}$
- Dividend Coverage: $(\text{Pre-Tax Income} + \text{Interest Expense}) / (\text{Interest Expense} + \text{Dividends})$
- Dividend Yield: $\text{Annual Dividends per Share} / \text{Current Market Price per Share}$

Indicator Trend

The fundamental indicator trend displays either quarterly scores over the past three years or annual scores over the past six years, depending on the reporting periods for the country. The best and worst scores can be easily determined from the values shown on the chart for each quarter or year.

Relative Valuation

The Relative Valuation Rating is based on a combination of three component factors: Price to Sales, Trailing P/E, and Forward P/E. Each factor is equally weighted. Equal deciles are then used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. These common valuation metrics are evaluated against the overall market, the index, and the company's own historic 5-year averages. A stock needs to have at least one of the three relative valuation factors in order to receive a score.

- Price to Sales: $\text{Close Price} / (\text{Sales for 4 Quarters or 1 Year} / \text{Shares Outstanding})$

- Trailing P/E: Close Price / Most Recent 4 Quarters or 1 Year of Earnings
- Forward P/E: Close Price / Upcoming 4 Quarters or 1 Year of Earnings

Valuation Averages

Negative values are excluded when calculating the averages. A maximum value of 100 is placed on Trailing P/E and Forward P/E, a maximum value of 5 is placed on Forward PEG, and a maximum value of 20 is placed on Price to Sales when calculating the averages. Higher values are rounded down to the maximum for the averages.

Valuation Multiples

The valuation multiples provide the Trailing P/E, Forward P/E, Forward PEG, and Price to Sales for the company and the relevant index average. In addition, a comparison of the current company's values to its 5-year average and an industry average are presented. A discount occurs when the company's ratio is valued more favorably (lower) than that to which it is compared.

Risk

The Risk Rating displays stocks on a scale of 1 to 10 with 10 being awarded to the least risky stocks. It is derived by looking at a series of long-term (5-year) and short-term (90-day) stock performance measures including volatility, magnitude of returns, beta, and correlation. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market. A stock needs to have at least two of the four risk factors in order to receive a score.

- Magnitude of Returns - The best / worst daily returns in the past 90 days and the best / worst monthly returns in the past 60 months.
- Volatility - The standard deviation of the stock price over the last 90 days and last 60 months, along with the average and largest intra-day stock swing.
- Beta - Measures the tendency of a security's returns to respond to swings in the market, based on the beta of the company versus the relevant index.
- Correlation - Determines how closely the returns of the stock and the relevant index move together, measured over the last 90 days and last 60 months.

Risk Analysis

Price analysis for the company and the relevant index is provided over two time periods. Daily analysis is provided for the last 90 days, whereas monthly statistics are used for the last 60 months.

Price Momentum

The Price Momentum Rating is based on a combination of two technical performance factors: relative strength and seasonality. The factors are equally weighted. Equal deciles are then used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have data for the relative strength factor in order to receive a score.

- Relative Strength - The relative strength of the company for the last 10 days, 50 days, and 200 days on a scale of 1 to 100.
- Seasonality - The average monthly return (price performance) for the current month and next 2 months for the company and industry, over the past 10 years. A lower industry rank indicates a higher return.

Price Performance

Daily close prices are used to calculate the price performance of the stock. The performance of the relevant index is also displayed as a means of comparison.

DISCLAIMER

© 2024 LSEG. All rights reserved. Republication or redistribution of LSEG content, including by framing or similar means, is prohibited without the prior written consent of LSEG. All information in this report is assumed to be accurate to the best of our ability. LSEG is not liable for any errors or delays in LSEG content, or for any actions taken in reliance on such content.

Any forward-looking statements included in the LSEG content are based on certain assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from current expectations. There is no assurance that any forward-looking statements will materialize.

The content in this LSEG report does not constitute investment advice or a recommendation to buy or sell securities of any kind. Past performance is not a guarantee of future results. Investors should consider this report as only a single factor when making an investment decision.